ScripAlthough financings of over $100m have become something of a rarity for Chinese biotechs, venture capital and private equity firms, as well as pharma companies, have recently made sizeable cash inject
ScripChinese biotechs are joining forces to leap into the fray of developing messenger RNA as cancer therapies, in another sign of catching up with global frontrunners in the race for cutting-edge drug mod
ScripThe front-runner in China’s growing crop of domestically developed mRNA COVID-19 vaccine candidates has run into a snag in a global Phase III study, with results now forecast to be delayed to early 20
ScripShanghai-based Everest Medicines Limited has become the latest Chinese biotech to leap into the mRNA fray through an in-licensing deal with the Canadian biotech Providence Therapeutics Holdings Inc